structural communications
Structure of tyrosine aminotransferase from Leishmania infantum
aDepartamento de Microbiología Molecular, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Calle Ramiro de Maeztu 9, 28040 Madrid, Spain, bSeattle Structural Genomics Center for Infectious Disease (SSGCID), USA, cSeattle Biomedical Research Institute, 307 Westlake Avenue North, Seattle, WA 98109, USA, dEmerald Bio Inc., 7869 NE Day Road West, Bainbridge Island, WA 98110, USA, and eDepartment of Global Health and Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA 98125, USA
*Correspondence e-mail: vlarraga@cib.csic.es
The trypanosomatid parasite Leishmania infantum is the causative agent of visceral leishmaniasis (VL), which is usually fatal unless treated. VL has an incidence of 0.5 million cases every year and is an important opportunistic co-infection in HIV/AIDS. Tyrosine aminotransferase (TAT) has an important role in the metabolism of trypanosomatids, catalyzing the first step in the degradation pathway of aromatic amino acids, which are ultimately converted into their corresponding L-2-oxoacids. Unlike the enzyme in Trypanosoma cruzi and mammals, L. infantum TAT (LiTAT) is not able to transaminate ketoglutarate. Here, the structure of LiTAT at 2.35 Å resolution is reported, and it is confirmed that the presence of two Leishmania-specific residues (Gln55 and Asn58) explains, at least in part, this specific reactivity. The difference in substrate specificity between leishmanial and mammalian TAT and the importance of this enzyme in parasite metabolism suggest that it may be a useful target in the development of new drugs against leishmaniasis.
Keywords: tyrosine aminotransferase; Leishmania infantum.
PDB reference: tyrosine aminotransferase, 4ix8
1. Introduction
The leishmaniases are a group of vector-borne parasitic diseases that threaten about 350 million people in 88 countries around the world, mostly in developing countries. Leishmania infantum (family Trypanosomatidae) is the causative agent of zoonotic visceral leishmaniasis (VL) in the Mediterranean basin, where dogs are the main reservoir. L. infantum is an important opportunistic human parasite, resulting in increasing co-infection with HIV (Cruz et al., 2006). A major outbreak of VL in humans has recently been reported in central Spain (Arce et al., 2013).
L. infantum has a digenetic biological life cycle, alternating between a mobile extracellular promastigote in the insect vector and an immobile intracellular amastigote in the mammalian host (Handman, 2001). Inside the gut of the sand-fly vector, an environment rich in proteins and amino acids (Rosenzweig et al., 2008), promastigotes undergo metacyclogenesis to increase their infectivity, and differentiate into amastigotes once inside the phagolysosome of mammalian phagocytes, where the availability of these nutrients is limited (McConville et al., 2007). Under these conditions, amino-acid catabolism becomes an important source of energy for the parasite by cytosolic NADH re-oxidation (Nowicki & Cazzulo, 2008) and methionine recycling (Berger et al., 2001; Berger et al., 1996).
Aromatic amino-acid catabolism is highly active in trypanosomatids, but degradation to CO2 and water is not complete as in mammals. This pathway consists of two steps leading to a reduced L-2-hydroxyacid product whose excretion has been correlated with virulence (Montemartini et al., 1994). The first step of this pathway is carried out by a tyrosine aminotransferase (TAT) belonging to the fold type I aminotransferases within the pyridoxal phosphate (PLP)-dependent superfamily (Jensen & Gu, 1996). One of the most studied enzymes belonging to this fold group is the broad substrate-specificity tyrosine aminotransferase from Trypanosoma cruzi (TcTAT), the structure of which has recently been resolved (Blankenfeldt et al., 1999; Montemartini et al., 1993, 1995).
However, the biological function of TAT in trypanosomatids is not yet clear, although previous studies detected an increase in transcript abundance of TAT in infective promastigotes of L. infantum (Alcolea et al., 2009) and in a benznidazole-resistant T. cruzi strain (Rego et al., 2008). These data suggest that TAT in trypanosomatids may play an important role in the infectivity of the parasite and its resistance against chemotherapy. We have solved the structure of L. infantum tyrosine aminotransferase (LiTAT) covalently bound to PLP, providing a structural basis for its enzymatic activity. The difference in substrate specificity between leishmanial and mammalian TAT and the importance of this enzyme in parasite metabolism suggest that it may be a promising target in the development of new drugs against leishmaniasis.
2. Methods
2.1. Protein expression and purification
The full-length LiTAT (LinJ.36.2490; NCBI XP_001469829.1) gene encoding a protein of 448 amino acids (UniProt A4IDL0) was PCR-amplified from L. infantum (MHOM/ES/98/10445) genomic DNA using containing BamHI and HindIII restriction sites (LiTAT_Fw, 5′-ACGGGATCCACGATTGATACGCAGGCC-3′, and LiTAT_Rv, 5′-ACGAAGCTTCTACTTCTTGTGGCGCTCGC-3′). A truncated version of the gene (LiTAT_truncated) lacking the first 114 of the annotated sequence was also amplified using containing the same restriction sites (LiTAT_truncated_Fw, 5′-ACGGGATCCACGAGTTTTCGCCGTATCGC-3′, and LiTAT_Rv). LiTAT and LiTAT_truncated were cloned into the pRSET-A vector (Invitrogen) and recombinant proteins were expressed in Escherichia coli BL21 (DE3) pLysS. Cells were grown in 3 l LB medium at 310 K until the OD600 reached 0.5. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added to a final concentration of 1 mM and induction continued for 2 h at 298 K, after which the harvested cells were frozen at 193 K. The frozen cell pellet was thawed and resuspended by vortexing in 200 ml lysis buffer [20 mM Tris–HCl pH 7.9, 500 mM NaCl, 4 µM PLP, 50 mM imidazole, 0.05 mg ml−1 lysozyme and protease-inhibitor cocktail (Roche, Basel, Switzerland; used following the manufacturer's instructions)]. The cell suspensions were lysed by sonication for 15 min and clarified by centrifugation on a Sorvall SS-34 at 27 000g. The clarified solutions were syringe-filtered through a 0.45 µm filter. The proteins were purified at room temperature by immobilized metal-affinity on a HisTrap FF 5 ml column (GE Healthcare) equilibrated with binding buffer (20 mM Tris–HCl pH 7.9, 500 mM NaCl, 4 µM PLP, 50 mM imidazole). The proteins were eluted with eight column volumes of elution buffer (20 mM Tris–HCl pH 7.9, 500 mM NaCl, 4 µM pyridoxal phosphate, 500 mM imidazole). was performed at room temperature using a HiLoad 26/60 Superdex 75 prep-grade column (GE Healthcare, Piscataway, New Jersey, USA) equilibrated in SEC buffer [20 mM HEPES pH 7.0, 300 mM NaCl, 5%(v/v) glycerol, 1 mM tris(2-carboxyethyl)phosphine hydrochloride]. Both proteins eluted as single peaks which correspond to the dimeric form in solution based on the estimated molecular weight. The obtained using the Low Molecular Weight Kit (GE Healthcare) allowed determination of the molecular weights of both proteins once the gel base value (Kav) has been calculated from the measured elution volume (Supplementary Fig. S11). Pooled fractions were concentrated at 277 K using an Amicon Ultra-15 30 kDa molecular-weight cutoff concentrator (Millipore, Billerica, Massachussets, USA) to 64.6 mg ml−1 for LiTAT and 51.6 mg ml−1 for LiTAT_truncated. The purity of both proteins was assessed to be >95% by SDS–PAGE.
2.2. Crystallization and structure solution
Purified LiTAT and LiTAT_truncated proteins were used for crystallization screening at 21.0 and 21.3 mg ml−1, respectively, using four sparse-matrix screens: JCSG+, MCSG1 (Emerald Bio), Morpheus and PACT (Molecular Dimensions). Hexagonal crystals were obtained under several conditions, but few diffracted well. Crystals of LiTAT_truncated from Morpheus screen condition B11 (10% PEG 4000, 20% glycerol, 30 mM NaF, 30 mM NaBr, 30 mM NaI, 100 mM Bicine/Tris–HCl pH 8.5) were vitrified by plunging them into liquid nitrogen. X-ray diffraction data were collected on LS-CAT beamline 21-ID-F at the Advanced Photon Source, Argonne National Laboratory at a temperature of 100 K using a Rayonix MX-225 detector.
The diffraction data were reduced with the XDS suite (Kabsch, 2010) to 2.35 Å resolution (Table 1). was performed with Phaser (McCoy et al., 2007) using the structure of TcTAT (PDB entry 1bw0; Blankenfeldt et al., 1999) as the search model. Molecular-replacement phases were improved including twofold NCS averaging with Parrot (Cowtan, 2010). An initial model was then built using Buccaneer (Cowtan, 2006). The model was then improved using iterative cycles of manual model building in Coot (Emsley et al., 2010) and with phenix.refine (Adams et al., 2010). The resolution cutoff was I/σ(I) > 2 for the highest shell.
‡Rwork = . §The free R factor was calculated with an equivalent equation to Rwork using 5% of the reflections that were omitted from the ¶Chen et al. (2010). |
Structure factors and coordinates have been deposited in the PDB as entry 4ix8.
2.3. Determination of the activity of LiTAT_truncated
The activity of LiTAT_truncated was assayed by the method of Diamondstone (1966) without the addition of diethylthiocarbamate. One unit of is defined as the amount of LiTAT that catalyzes the formation of 1 µmol p-hydroxyphenylpyruvate (measured as p-hydroxybenzaldehyde). The final enzymatic activity values are the means of four determinations.
3. Results and discussion
3.1. Comparison of LiTAT with other closely related aminotransferases
The primary sequence of the TAT protein is highly conserved among all Leishmania spp., while orthologues annotated in other trypanosomatids, such as T. cruzi, T. rangeli and Crithidia acanthocephali, show <50% sequence identity to the Leishmania sequence. L. infantum contains only a single copy of the TAT gene (LinJ.36.2490), while in T. cruzi there are around 70 copies of the TcTAT gene (Bontempi et al., 1993). Interestingly, the TAT gene appears to be absent from the African trypanosomes (such as T. brucei), which do not have an intracellular immobile stage where the availability of nutrients is limited. Sequence alignment (Supplementary Fig. S2) shows a low degree of sequence identity between LiTAT and mammalian liver TAT (37%) and also between LiTAT and TcTAT (44%). Interestingly, the N-terminal 38 amino acids of mammalian liver TAT which were previously proposed to be involved in the rapid degradation of the protein (Hargrove et al., 1989) are present in LiTAT (albeit with little sequence conservation) and are absent from the T. cruzi enzyme.
3.2. of LiTAT
The N-terminal domain was too disordered to be modelled in full-length LiTAT, but its deletion in LiTAT_truncated did not affect the overall structure of the protein. Indeed, the best resolution (2.35 Å) was achieved for the LiTAT_truncated PLP-bound structure. The final model has a crystallographic R value of 17.3% and an Rfree value of 20.3% (Table 1). The of the crystal in P3221 is formed by two identical polypeptide chains (A and B), forming a homodimer that is also present in solution (see Supplementary Fig. S1). For chain A residues Ser40–Lys448 could be built, while for chain B only residues Ser40–Ile439 could be built. However, several loop regions (Asp62–Asn63 in chain A and Asp62–Ser72, Glu363–Gly367, Lys382–Ser393 and Glu404–Glu405 in chain B) were too disordered to be modelled.
The five closest structural homologues of LiTAT were identified using the DaliLite v.3 server (Holm & Rosenström, 2010): TcTAT (PDB entry 1bw0; Z-score 59.2, 44% identity; Blankenfeldt et al., 1999), TAT from Homo sapiens (PDB entry 3dyd; Z-score 54.4, 37% identity; Structural Genomics Consortium, unpublished work), alanine aminotransferase from Pyrococcus furiosus (PDB entry 1xi9; Z-score 53.1, 28% identity; Southeast Collaboratory for Structural Genomics, unpublished work), TAT from Mus musculus (PDB entry 3pdx; Z-score 52.8, 38% identity; Mehere et al., 2010) and α-aminotransferase from P. horikoshii (PDB entry 1gd9; Z-score 48.4, 22% identity; Ura et al., 2001). These alignments show the low percentage similarity between LiTAT and the other closely related orthologues.
The structure of each LiTAT subunit shows the typical fold type I of the aminotransferases (McPhalen et al., 1992), with each monomer having two domains (Fig. 1). The larger of these domains (Asp91–Arg339) forms an internal core of seven sheets with β2 antiparallel to the rest. The core of the β-sheets is enclosed by α-helices. The smaller discontinuous domain comprises residues from the N-terminus (Lys65–Pro90) and C-terminus (Thr340–Lys448) which are involved in substrate recognition. As in TcTAT, the N-terminal residues (Ser40–Ser47) of LiTAT_truncated are involved in interaction between subunits (Blankenfeldt et al., 1999).
LiTAT contains 13 cysteine residues per subunit; however, there are no disulfide bonds. Thus, it appears that the disulfide bond-mediated inactivation observed for mammalian TATs (Mehere et al., 2010) is not used in LiTAT.
3.3. Substrate recognition
Reversible transamination reactions are a bi-bi ping-pong mechanism (Kirsch et al., 1984), and tyrosine aminotransferases catalyze the transamination of an amino group from the donor to the covalently bound PLP to form pyridoxamine phosphate (PMP; Fig. 2). The second step of the reaction transfers the amino group to the carbonyl moiety of an amino acceptor, regenerating the In both subunits of LiTAT, PLP is covalently bound to Lys286 in a cavity located at the interface between the subunits, although these cavities are not adjacent in the dimer (Fig. 3). However, residues from both subunits participate in the stabilization of PMP and their disposition is similar between LiTAT and TcTAT, although Thr184 and Tyr345 in TcTAT are replaced by Ile221 and Phe378 in LiTAT. Since the hydroxyl group of Tyr345 is oriented towards the internal aldimine, replacement by Phe378 in LiTAT may affect the reactivity of PLP with the amino donor and/or acceptor.
Unlike TcTAT (and mammalian TATs), LiTAT is not able to transaminate α-ketoglutarate using tyrosine as the amino donor (0.32 ± 0.17 U per milligram of purified protein), although it can transaminate pyruvate with high efficiency (82.3 ± 0.79 U per milligram of purified protein), consistent with the published activity of the L. major orthologue (Marciano et al., 2009).
Site-directed mutagenesis studies using rat TAT and TcTAT showed that the ability to transaminate dicarboxylic substrates was likely to be owing to the presence of residues Asn54 and Arg57 (Asn17 and Arg20 in TcTAT) helping to orient the amino acceptors towards the et al., 2003). These residues, which are conserved in most orthologues of tyrosine aminotransferases, are not present in LiTAT, where they are replaced by Gln55 and Asn58. While the side chain of Asn58 was not well resolved in our model, the side chain of Gln55 is less oriented towards the substrate-binding pocket than Asn17 in TcTAT (Fig. 4). Thus, we postulate that the difference in the specificity of Leishmania TATs is related to these amino-acid substitutions by altering the hydrogen-bonding interaction with the oxoacid substrates.
(Sobrado4. Conclusion
We have obtained a 2.35 Å resolution structure of tyrosine aminotransferase from L. infantum, which correlates well with those of other tyrosine aminotransferases. However, unlike other aminotransferases, Leishmania TAT is not able to transaminate dicarboxylic substrates and its preferred substrate is pyruvate. This can be explained by the substitution of the critical residues Asn54 and Arg57 found in other TAT orthologues by Gln55 and Asn58 in LiTAT. This difference in substrate activity, as well as the relevance of the enzyme to the life cycle of the parasite, highlight the importance of this enzyme as a potential candidate for the development of inhibitors in the near future.
5. Related literature
The following references are cited in the Supporting Information for this article: Gouet et al. (1999, 2003).
Supporting information
PDB reference: tyrosine aminotransferase, 4ix8
Supporting Information. DOI: https://doi.org/10.1107/S2053230X14007845/hv5256sup1.pdf
Acknowledgements
The authors thank the whole SSGCID team. This research was funded under Federal Contract No. HHSN272201200025C from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. The project was also funded by grant AGL 2010-21806-C02-01 from the Spanish Ministry of Economy and Competitiveness and by contract No. 050204100014 from Fundación Ramón Areces. MAM thanks the National Research Council for grant 2012EST JAE Predoc.
References
Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221. Web of Science CrossRef CAS IUCr Journals Google Scholar
Alcolea, P. J., Alonso, A., Sánchez-Gorostiaga, A., Moreno-Paz, M., Gómez, M. J., Ramos, I., Parro, V. & Larraga, V. (2009). Genomics, 93, 551–564. Web of Science CrossRef PubMed CAS Google Scholar
Arce, A., Estirado, A., Ordobas, M., Sevilla, S., García, N., Moratilla, L., de la Fuente, S., Martínez, A. M., Pérez, A. M., Aránguez, E., Iriso, A., Sevillano, O., Bernal, J. & Vilas, F. (2013). Euro Surveill. 18, 20546. Web of Science PubMed Google Scholar
Berger, B. J., Dai, W. W., Wang, H., Stark, R. E. & Cerami, A. (1996). Proc. Natl Acad. Sci. USA, 93, 4126–4130. CrossRef CAS PubMed Web of Science Google Scholar
Berger, L. C., Wilson, J., Wood, P. & Berger, B. J. (2001). J. Bacteriol. 183, 4421–4434. Web of Science CrossRef PubMed CAS Google Scholar
Blankenfeldt, W., Nowicki, C., Montemartini-Kalisz, M., Kalisz, H. M. & Hecht, H.-J. (1999). Protein Sci. 8, 2406–2417. Web of Science CrossRef PubMed CAS Google Scholar
Bontempi, E. J., Búa, J., Aslund, L., Porcel, B., Segura, E. L., Henriksson, J., Orn, A., Pettersson, U. & Ruiz, A. M. (1993). Mol. Biochem. Parasitol. 59, 253–262. CrossRef CAS PubMed Web of Science Google Scholar
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. Web of Science CrossRef CAS IUCr Journals Google Scholar
Cowtan, K. (2006). Acta Cryst. D62, 1002–1011. Web of Science CrossRef CAS IUCr Journals Google Scholar
Cowtan, K. (2010). Acta Cryst. D66, 470–478. Web of Science CrossRef CAS IUCr Journals Google Scholar
Cruz, I., Nieto, J., Moreno, J., Cañavate, C., Desjeux, P. & Alvar, J. (2006). Indian J. Med. Res. 123, 357–388. Web of Science PubMed Google Scholar
Diamondstone, T. I. (1966). Anal. Biochem. 16, 395–401. CrossRef CAS Web of Science Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Gouet, P., Courcelle, E., Stuart, D. I. & Métoz, F. (1999). Bioinformatics, 15, 305–308. Web of Science CrossRef PubMed CAS Google Scholar
Gouet, P., Robert, X. & Courcelle, E. (2003). Nucleic Acids Res. 31, 3320–3323. Web of Science CrossRef PubMed CAS Google Scholar
Handman, E. (2001). Clin. Microbiol. Rev. 14, 229–243. Web of Science CrossRef PubMed CAS Google Scholar
Hargrove, J. L., Scoble, H. A., Mathews, W. R., Baumstark, B. R. & Biemann, K. (1989). J. Biol. Chem. 264, 45–53. CAS PubMed Web of Science Google Scholar
Holm, L. & Rosenström, P. (2010). Nucleic Acids Res. 38, W545–W549. Web of Science CrossRef CAS PubMed Google Scholar
Jensen, R. A. & Gu, W. (1996). J. Bacteriol. 178, 2161–2171. CAS PubMed Web of Science Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Kirsch, J. F., Eichele, G., Ford, G. C., Vincent, M. G., Jansonius, J. N., Gehring, H. & Christen, P. (1984). J. Mol. Biol. 174, 497–525. CrossRef CAS PubMed Web of Science Google Scholar
Marciano, D., Maugeri, D. A., Cazzulo, J. J. & Nowicki, C. (2009). Mol. Biochem. Parasitol. 166, 172–182. Web of Science CrossRef PubMed CAS Google Scholar
McConville, M. J., de Souza, D., Saunders, E., Likic, V. A. & Naderer, T. (2007). Trends Parasitol. 23, 368–375. Web of Science CrossRef PubMed CAS Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
McPhalen, C. A., Vincent, M. G., Picot, D., Jansonius, J. N., Lesk, A. M. & Chothia, C. (1992). J. Mol. Biol. 227, 197–213. CrossRef PubMed CAS Web of Science Google Scholar
Mehere, P., Han, Q., Lemkul, J. A., Vavricka, C. J., Robinson, H., Bevan, D. R. & Li, J. (2010). Protein Cell, 1, 1023–1032. Web of Science CrossRef CAS PubMed Google Scholar
Montemartini, M., Búa, J., Bontempi, E., Zelada, C., Ruiz, A. M., Santomé, J. A., Cazzulo, J. J. & Nowicki, C. (1995). FEMS Microbiol. Lett. 133, 17–20. CrossRef CAS PubMed Google Scholar
Montemartini, M., Santomé, J. A., Cazzulo, J. J. & Nowicki, C. (1993). Biochem. J. 292, 901–906. CAS PubMed Web of Science Google Scholar
Montemartini, M., Santomé, J. A., Cazzulo, J. J. & Nowicki, C. (1994). FEMS Microbiol. Lett. 118, 89–92. CAS PubMed Web of Science Google Scholar
Nowicki, C. & Cazzulo, J. J. (2008). Comp. Biochem. Physiol. A Mol. Integr. Physiol. 151, 381–390. Web of Science CrossRef PubMed Google Scholar
Rego, J. V., Murta, S. M., Nirdé, P., Nogueira, F. B., de Andrade, H. M. & Romanha, A. J. (2008). Exp. Parasitol. 118, 111–117. Web of Science CrossRef PubMed CAS Google Scholar
Rosenzweig, D., Smith, D., Opperdoes, F., Stern, S., Olafson, R. W. & Zilberstein, D. (2008). FASEB J. 22, 590–602. Web of Science CrossRef PubMed CAS Google Scholar
Sobrado, V. R., Montemartini-Kalisz, M., Kalisz, H. M., De La Fuente, M. C., Hecht, H.-J. & Nowicki, C. (2003). Protein Sci. 12, 1039–1050. Web of Science CrossRef PubMed CAS Google Scholar
Ura, H., Harata, K., Matsui, I. & Kuramitsu, S. (2001). J. Biochem. (Tokyo), 129, 173–178. CrossRef PubMed CAS Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.